Alirocumab

Adult: Adjunct to diet, alone or in combination with statin therapy and/or other lipid-lowering treatments: Initially, 75 mg once every 2 weeks. Alternatively, an initial dose of 150 mg once every 2 weeks or 300 mg once every 4 weeks may be given in patients requiring >60% LDL-C reduction. If LDL-C response is inadequate for the 75 mg once every 2 weeks or 300 mg once every 4 weeks initial dosing, the dose may be adjusted to a Max of 150 mg once every 2 weeks. Assess LDL-C levels within 4-8 weeks after treatment initiation or titration and adjust the dose if needed. Individualise dosing according to the patient's baseline LDL-C level, goals of therapy, and response. Dosage and treatment recommendations may vary between countries (refer to detailed local guidelines).

Adult: To reduce the risk of CV events (e.g. MI, stroke, unstable angina requiring hospitalisation) by decreasing LDL-C levels in patients with established atherosclerotic CV disease: Alone or in combination with the maximally tolerated statin dose and/or other lipid-lowering therapies: Initially, 75 mg once every 2 weeks. Alternatively, an initial dose of 150 mg once every 2 weeks or 300 mg once every 4 weeks may be given in patients requiring >60% LDL-C reduction. If LDL-C response is inadequate for the 75 mg once every 2 weeks or 300 mg once every 4 weeks initial dosing, the dose may be adjusted to a Max of 150 mg once every 2 weeks. Assess LDL-C levels within 4-8 weeks after treatment initiation or titration and adjust the dose if needed. Individualise dosing according to the patient's baseline LDL-C level, goals of therapy, and response. Dosage and treatment recommendations may vary between countries (refer to detailed local guidelines).